27493840|t|Evaluation of Pharmacokinetics, and Bioavailability of Higher Doses of Tocotrienols in Healthy Fed Humans
27493840|a|Tocotrienols has been known to lower serum lipid parameters below 500 mg/d, while increase lipid parameters at higher dose of 750 mg/d. δ-Tocotrienol has a novel inflammatory property of concentration-dependent inhibition and activation. Therefore, inhibition (anti-inflammatory) property of tocotrienols at low doses is useful for cardiovascular disease, whereas, activation (pro-inflammatory) property using high dose is found effective for treatments of various types of cancer. We have recently described plasma bioavailability of 125 mg/d, 250 mg/d and 500 mg/d doses of δ-tocotrienol in healthy fed subjects, which showed dose-dependent increases in area under the curve (AUC) and maximum concentration (Cmax). Hence, in the current study, higher doses of tocotrienols have used to analyze its effect on plasma pharmacokinetic parameters. To evaluate the safety and bioavailability of higher doses (750 mg and 1000 mg) of annatto -based tocotrienols in healthy fed subjects. All four isomers (α-, β-, γ-, δ-) of tocols (tocotrienols and tocopherols) present in the plasmas of subjects were quantified and analyzed for various pharmacokinetic parameters. An open-label, randomized study was performed to analyze pharmacokinetics and bioavailability of δ-tocotrienol in 6 healthy fed subjects. All subjects (3/ dose) were randomly assigned to one of each dose of 750 mg or 1000 mg. Blood samples were collected at 0, 1, 2, 4, 6, 8 h intervals and all isomers of α-, β-, γ-, δ-tocotrienols, and tocopherols in plasmas were quantified by HPLC. Oral administration of 750 and 1000 mg/d of tocotrienols resulted in dose-dependent increases in plasmas (ng/ml) AUC t0-t8 6621, 7450; AUC t0-∞ 8688, 9633; AUMC t0-∞ 52497, 57199; MRT 6.04, 5.93; Cmax 1444, 1592 (P<0.05), respectively, of δ-tocotrienol isomer. Moreover, both doses also resulted in plasmas Tmax 3.33-4 h; elimination half-life (t1/2 h) 2.74, 2.68; time of clearance (Cl-T, l/h) 0.086, 0.078; volume of distribution (Vd/f, mg/h) 0.34, 0.30; and elimination rate constant (ke; h(-1)) 0.25, 0.17, respectively of δ- tocotrienol isomer. Similar results of these parameters were reported for γ-tocotrienol, β- tocotrienol, α-tocotrienol, δ-tocopherol, γ-tocopherol, and β-tocopherol, except for α- tocopherol. This study has described pharmacokinetics using higher doses of 750 mg/d and 1000 mg/d of δ-tocotrienol. These results confirmed earlier findings that Tmax was 3-4 h for all isomers of tocotrienols and tocopherols except for α-tocopherol (6 h). These higher doses of tocotrienols were found safe in humans and may be useful for treatments of various types of cancer, diabetes, and Alzheimer's disease.
27493840	0	10	Evaluation	T058	C0220825
27493840	14	30	Pharmacokinetics	T039	C0031327
27493840	36	51	Bioavailability	T081	C0005508
27493840	55	61	Higher	T080	C0205250
27493840	62	67	Doses	T081	C0178602
27493840	71	83	Tocotrienols	T109,T121,T127	C0949647
27493840	87	94	Healthy	T080	C3898900
27493840	99	105	Humans	T016	C0086418
27493840	106	118	Tocotrienols	T109,T121,T127	C0949647
27493840	137	165	lower serum lipid parameters	T047	C0856969
27493840	188	213	increase lipid parameters	T033	C0856968
27493840	217	223	higher	T080	C0205250
27493840	224	228	dose	T081	C0178602
27493840	242	255	δ-Tocotrienol	T109,T121	C0218003
27493840	268	280	inflammatory	T169	C0333348
27493840	281	289	property	T080	C0871161
27493840	293	316	concentration-dependent	T081	C0392762
27493840	317	327	inhibition	T052	C3463820
27493840	332	342	activation	T052	C1879547
27493840	355	365	inhibition	T052	C3463820
27493840	367	384	anti-inflammatory	T080	C1515999
27493840	386	394	property	T080	C0871161
27493840	398	410	tocotrienols	T109,T121,T127	C0949647
27493840	414	417	low	T080	C0205251
27493840	418	423	doses	T081	C0178602
27493840	438	460	cardiovascular disease	T047	C0007222
27493840	471	481	activation	T052	C1879547
27493840	483	499	pro-inflammatory	T169	C0333348
27493840	501	509	property	T080	C0871161
27493840	516	520	high	T080	C0205250
27493840	521	525	dose	T081	C0178602
27493840	535	544	effective	T080	C1704419
27493840	549	559	treatments	T061	C0087111
27493840	580	586	cancer	T191	C0006826
27493840	615	621	plasma	T031	C0032105
27493840	622	637	bioavailability	T081	C0005508
27493840	673	678	doses	T081	C0178602
27493840	682	695	δ-tocotrienol	T109,T121	C0218003
27493840	699	706	healthy	T080	C3898900
27493840	711	719	subjects	T098	C2349001
27493840	734	748	dose-dependent	T081	C1512045
27493840	749	782	increases in area under the curve	T033	C1708492
27493840	784	787	AUC	T081	C0376690
27493840	793	814	maximum concentration	T081	C2347813
27493840	816	820	Cmax	T081	C2347813
27493840	852	858	higher	T080	C0205250
27493840	859	864	doses	T081	C0178602
27493840	868	880	tocotrienols	T109,T121,T127	C0949647
27493840	916	922	plasma	T031	C0032105
27493840	923	949	pharmacokinetic parameters	T170	C1705911
27493840	954	962	evaluate	T058	C0220825
27493840	967	973	safety	T068	C0036043
27493840	978	993	bioavailability	T081	C0005508
27493840	997	1003	higher	T080	C0205250
27493840	1004	1009	doses	T081	C0178602
27493840	1034	1041	annatto	T109,T121,T123,T130	C0051928
27493840	1049	1061	tocotrienols	T109,T121,T127	C0949647
27493840	1065	1072	healthy	T080	C3898900
27493840	1077	1085	subjects	T098	C2349001
27493840	1096	1103	isomers	UnknownType	C0683115
27493840	1124	1130	tocols	T109,T121	C0599549
27493840	1132	1144	tocotrienols	T109,T121,T127	C0949647
27493840	1149	1160	tocopherols	T109,T121,T127	C0087096
27493840	1177	1184	plasmas	T031	C0032105
27493840	1188	1196	subjects	T098	C2349001
27493840	1217	1225	analyzed	T062	C0936012
27493840	1238	1264	pharmacokinetic parameters	T170	C1705911
27493840	1269	1279	open-label	T062	C1709323
27493840	1281	1297	randomized study	T062	C2986910
27493840	1323	1339	pharmacokinetics	T039	C0031327
27493840	1344	1359	bioavailability	T081	C0005508
27493840	1363	1376	δ-tocotrienol	T109,T121	C0218003
27493840	1382	1389	healthy	T080	C3898900
27493840	1394	1402	subjects	T098	C2349001
27493840	1408	1416	subjects	T098	C2349001
27493840	1421	1425	dose	T081	C0178602
27493840	1441	1449	assigned	T169	C1516050
27493840	1465	1469	dose	T081	C0178602
27493840	1492	1505	Blood samples	T031	C0178913
27493840	1561	1568	isomers	UnknownType	C0683115
27493840	1572	1574	α-	T109,T121	C0217873
27493840	1576	1578	β-	T109,T121	C0217992
27493840	1580	1582	γ-	T109,T121	C0206999
27493840	1584	1598	δ-tocotrienols	T109,T121	C0218003
27493840	1604	1615	tocopherols	T109,T121,T127	C0087096
27493840	1619	1626	plasmas	T031	C0032105
27493840	1646	1650	HPLC	T059	C0008562
27493840	1652	1671	Oral administration	T061	C0001563
27493840	1696	1708	tocotrienols	T109,T121,T127	C0949647
27493840	1721	1735	dose-dependent	T081	C1512045
27493840	1736	1745	increases	T081	C0205217
27493840	1749	1756	plasmas	T031	C0032105
27493840	1765	1768	AUC	T081	C0376690
27493840	1787	1790	AUC	T081	C0376690
27493840	1808	1812	AUMC	T081	C2827743
27493840	1832	1835	MRT	T081	C2827742
27493840	1848	1852	Cmax	T081	C2347813
27493840	1891	1911	δ-tocotrienol isomer	T109,T121	C0218003
27493840	1928	1933	doses	T081	C0178602
27493840	1951	1958	plasmas	T031	C0032105
27493840	1959	1963	Tmax	T081	C2348796
27493840	1974	1995	elimination half-life	T081	C2348397
27493840	1997	2001	t1/2	T081	C2348397
27493840	2017	2034	time of clearance	T079	C1254367
27493840	2036	2040	Cl-T	T079	C1254367
27493840	2061	2083	volume of distribution	T081	C0683148
27493840	2085	2089	Vd/f	T081	C0683148
27493840	2113	2138	elimination rate constant	T081	C2986811
27493840	2140	2142	ke	T081	C2986811
27493840	2179	2200	δ- tocotrienol isomer	T109,T121	C0218003
27493840	2210	2217	results	T033	C0683954
27493840	2227	2237	parameters	T033	C0449381
27493840	2243	2251	reported	T058	C0700287
27493840	2256	2269	γ-tocotrienol	T109,T121	C0206999
27493840	2271	2285	β- tocotrienol	T109,T121	C0217992
27493840	2287	2300	α-tocotrienol	T109,T121	C0217873
27493840	2302	2314	δ-tocopherol	T109,T121,T127	C0304915
27493840	2316	2328	γ-tocopherol	T109,T121,T127	C0017054
27493840	2334	2346	β-tocopherol	T109,T121,T127	C0005287
27493840	2359	2372	α- tocopherol	T109,T121,T127	C0969677
27493840	2399	2415	pharmacokinetics	T039	C0031327
27493840	2422	2428	higher	T080	C0205250
27493840	2429	2434	doses	T081	C0178602
27493840	2464	2477	δ-tocotrienol	T109,T121	C0218003
27493840	2485	2492	results	T033	C0683954
27493840	2493	2502	confirmed	T080	C0521093
27493840	2525	2529	Tmax	T081	C2348796
27493840	2548	2555	isomers	UnknownType	C0683115
27493840	2559	2571	tocotrienols	T109,T121,T127	C0949647
27493840	2576	2587	tocopherols	T109,T121,T127	C0087096
27493840	2599	2611	α-tocopherol	T109,T121,T127	C0969677
27493840	2625	2631	higher	T080	C0205250
27493840	2632	2637	doses	T081	C0178602
27493840	2641	2653	tocotrienols	T109,T121,T127	C0949647
27493840	2673	2679	humans	T016	C0086418
27493840	2702	2712	treatments	T061	C0087111
27493840	2733	2739	cancer	T191	C0006826
27493840	2741	2749	diabetes	T047	C0011847
27493840	2755	2774	Alzheimer's disease	T047	C0002395